Singulera Therapeutics Inc. has applied to register the trademark SINGULERA with the US Patent and Trademark Office for organotherapy preparations, pharmaceutical preparations for cell therapy for medical purposes and pharmaceutical preparations for gene therapy for medical purposes (Class 5: pharmaceuticals and supplements), and for goods or services in 3 other classes. The filing basis is a registration or application outside the United States (USPTO record, serial 50145475, October 5, 2026).
Is this your company?
Free check on Singulera Therapeutics Inc.: what is on record about the company behind this mark →
Singulera Therapeutics Inc., a corporation organized in Illinois, applied to register the trademark SINGULERA with the United States Patent and Trademark Office on 2026-10-05, serial number 50145475. The application covers 4 classes of goods and services, Class 5 (Pharmaceuticals and supplements); Class 40 (Material treatment); Class 42 (Software as a service and technology services); Class 44 (Medical and beauty services), and is based on a registration or application outside the United States. The latest step on the record is "Application filing receipt mailed" on 2026-10-05.
| Mark | SINGULERA |
|---|---|
| Applicant | Singulera Therapeutics Inc., a corporation organized in Illinois |
| Applicant's location | Chicago, Illinois |
| Serial number | 50145475 |
| Filed | 2026-10-05 |
| Filing basis | A registration or application outside the united states |
| Classes | Class 5 (Pharmaceuticals and supplements); Class 40 (Material treatment); Class 42 (Software as a service and technology services); Class 44 (Medical and beauty services) |
| Latest step on the record | Application filing receipt mailed, 2026-10-05 |
| Mark description | The mark consists of the wording "Singulera" in a stylized font. |
Want the whole picture on Singulera Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Singulera Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Singulera Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What will SINGULERA be used for?
Class 5 (Pharmaceuticals and supplements)
Syringes sold filled with pharmaceuticals for the treatment of osteoarthritis and other degenerative joint diseases; Syringes sold filled with pharmaceuticals for chronic wound healing, including non-healing ulcers; Syringes sold filled with immune-modulating pharmaceuticals for autoimmune diseases and transplant rejection prevention; Syringes sold filled with pharmaceuticals for cardiovascular diseases, including acute myocardial infarction and ischemic conditions; Syringes sold filled with regenerative pharmaceuticals for skin and tissue repair; Organotherapy preparations; Biological preparations for use in cell cultures for medical purposes; Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Pharmaceutical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; Pharmaceutical preparations for cell therapy for medical purposes; Pharmaceutical preparations for gene therapy for medical purposes; Pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; Pharmaceutical preparations for therapies to modulate the immune system; Pharmaceutical preparations for therapeutic delivery of nucleic acids; Medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Stem cells for medical purposes; Opotherapy preparations; Biological reagent for medical purposes; Immunostimulants
Class 40 (Material treatment)
Custom manufacturing of pharmaceuticals; Custom manufacturing of biological tissue, blood, cell and genetic material; Custom manufacturing of biological preparations; Custom biomanufacturing of pharmaceutical preparations; Custom biomanufacturing of pharmaceuticals containing cultured cells for use in cell therapy; Custom manufacturing of cell therapy preparations; Contract biomanufacturing in the field of pharmaceuticals
Class 42 (Software as a service and technology services)
Biological research; Biotechnological research; Medical research; Research and development of new products for others; Technological research in the field of biotechnology; Conducting technical project studies; Industrial research in the field of biotechnology; Research and development of pharmaceutical preparations; Conducting clinical trials for others; Research and development in the field of cell therapy; Research and development in the field of biopharmaceuticals; Research and development of pharmaceutical manufacturing processes; Research and development of biopharmaceutical manufacturing processes; Testing and analysis of pharmaceutical products
Class 44 (Medical and beauty services)
Medical services; Medical and pharmaceutical consultation; Providing medical information; Stem cell therapy services; Immunotherapy services; Medical treatment services for autoimmune diseases; Medical services for the prevention and treatment of organ transplant rejection
Where does the application stand?
| Date | Step on the record |
|---|---|
| 2026-10-05 | New application entered |
| 2026-10-05 | Application filing receipt mailed |
SINGULERA is the only trademark application Singulera Therapeutics Inc. filed in the last 90 days, as far as the USPTO's daily records show.
MentionFox follows a brand's mentions across social platforms, news, forums and reviews. Sign up and SINGULERA is already filled in as the brand to track.
Monitor mentions of SINGULERAGetFoxChat puts an AI chat operator on your website that answers visitors from your own pages. Check your site to see what it would answer.
Check your site with GetFoxChatWho runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Singulera Therapeutics Inc.Where this comes from
A company that wants to protect a new brand name in the United States files a trademark application with the United States Patent and Trademark Office. The application names the mark, the company applying, the classes of goods and services it will be used for, in the company's own words, and whether the brand is already on sale or is still to launch. Each application gets a serial number and a public record that follows it through examination.
Every fact on this page is taken from that record and linked to it. MentionFox lists applications by companies only, corporations and limited liability companies; applications filed by individuals are not listed. A filing shows a company's plans for a name; it does not show sales, and an application can still be refused or abandoned.